More than 11,000 bottles of a common blood pressure medicine were pulled nationwide because the tablets may not dissolve as intended.
Quick Take
- The recall covers 11,460 bottles of chlorthalidone tablets sold across the United States.[1][3]
- The problem is failed dissolution specifications, meaning the tablets may not break down properly in the body.[2][3]
- The affected products are 25-milligram tablets in100-count and 1,000-count bottles.[1][3]
- The FDA has not yet assigned a recall class in the available reports, which leaves some uncertainty about severity.[1][3]
What Was Recalled and Why
The recalled product is chlorthalidone, a diuretic often used to treat high blood pressure and fluid retention.[1][3] The reports say that Inventia Healthcare Limited initiated a voluntary recall on June 5, and that Rising Pharma Holdings distributed the bottles in the United States.[1][3]
The affected bottles have lot numbers RISA24001 and RISB24002 and an expiration date of April 2027.[1][3]
The key issue is not contamination or a broken label. It is dissolution. That sounds technical, but it matters in plain English. If a tablet does not dissolve properly, the body may not absorb the full dose. That can weaken the drug’s effect and leave blood pressure less controlled than expected.[2][3]
Why Dissolution Problems Get Attention
Dissolution problems fall into a gray area that can still worry regulators and patients. The tablet may look normal. It may even pass through the bottle without any sign of trouble. But if it does not break apart at the right rate, the medicine can fail at the very point that matters most: inside the body.[2][4]
That is why the FDA treats these failures as real quality problems, even when no injuries have been reported.[4]
That caution is part of a broader pattern in drug recalls. Quality assurance problems account for a large share of recalls, and dissolution failures are a recurring issue in that mix.[8][11][13]
In other words, this is not a strange one-off. It is the sort of manufacturing defect that regulators know can slip past the eye but still affect treatment.
What Patients Should Do Now
Reports tied to the FDA say consumers should check the bottle label and lot number against the recall notice.[14] The FDA also advises people to talk with a pharmacist or health care provider if their medicine matches the recalled lots.[14]
One point matters above all: do not stop taking blood pressure medicine on your own unless a clinician tells you to. Sudden changes can create their own risks, especially for people already managing hypertension.
FDA recalls 11,460 bottles of Chlorthalidone after dissolution failures threaten drug effectiveness, prompting a voluntary recall by Inventia Healthcare. What this means for patients and clinicians, and how safety testing squares with access to essential meds. pic.twitter.com/c2BANZm4iV
— Azat TV (@azattelevision) June 22, 2026
The bigger story here is how fast a small manufacturing failure can become a national worry. A recall does not always mean a drug is dangerous in the dramatic sense. Sometimes it means the system caught a product that may not work as promised.
That is less sensational than panic, but more serious than it first appears. For patients, the real test is simple: verify the lot, ask the pharmacist, and stay on the safest path forward.
Sources:
[1] Web – Thousands of bottles of blood pressure medication recalled nationwide
[2] Web – FDA Announces Recall of Common Blood Pressure Medication
[3] Web – FDA recalls 11,460 bottles of chlorthalidone blood pressure tablets
[4] Web – The recall applies to 100- and 1,000-tablet bottles of Chlorthalidone …
[8] Web – Blood pressure medication recalled nationwide over manufacturing …
[11] Web – Drug Recall Report – Washington State Local Health Insurance
[13] Web – The FDA recalled 11,460 bottles of chlorthalidone tablets, USP, 25 …
